

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
MERCKEN, et al.

Examiner: Not Yet Known

Art Unit: Not Yet Known

Application No.: Not Yet Assigned

Filed: **October 22, 2003**

Title: **INHIBITORS OF SRC KINASE FOR
USE IN ALZHEIMER'S DISEASE**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, on

22 October 2003

Date of Deposit

Signature

EL 964841507 US


Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,



Michael Schmelzer, Reg. No. 43,093
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4797
Telefax (908) 231-2626

Aventis Docket No. FRAV2002/0030 US NP